JPWO2020095256A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020095256A5 JPWO2020095256A5 JP2021524166A JP2021524166A JPWO2020095256A5 JP WO2020095256 A5 JPWO2020095256 A5 JP WO2020095256A5 JP 2021524166 A JP2021524166 A JP 2021524166A JP 2021524166 A JP2021524166 A JP 2021524166A JP WO2020095256 A5 JPWO2020095256 A5 JP WO2020095256A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- hydrogen
- composition
- conh
- nhc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025006295A JP2025063207A (ja) | 2018-11-08 | 2025-01-16 | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841042108 | 2018-11-08 | ||
| IN201841042108 | 2018-11-08 | ||
| PCT/IB2019/059602 WO2020095256A1 (en) | 2018-11-08 | 2019-11-08 | Combination of small molecule cd-47 inhibitors with other anti-cancer agents |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006295A Division JP2025063207A (ja) | 2018-11-08 | 2025-01-16 | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022507025A JP2022507025A (ja) | 2022-01-18 |
| JPWO2020095256A5 true JPWO2020095256A5 (https=) | 2022-11-11 |
| JP2022507025A5 JP2022507025A5 (https=) | 2022-11-11 |
| JP7623279B2 JP7623279B2 (ja) | 2025-01-28 |
Family
ID=69159806
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524166A Active JP7623279B2 (ja) | 2018-11-08 | 2019-11-08 | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
| JP2025006295A Pending JP2025063207A (ja) | 2018-11-08 | 2025-01-16 | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006295A Pending JP2025063207A (ja) | 2018-11-08 | 2025-01-16 | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11311517B2 (https=) |
| EP (1) | EP3876931A1 (https=) |
| JP (2) | JP7623279B2 (https=) |
| KR (1) | KR20210088584A (https=) |
| CN (2) | CN112930181B (https=) |
| AU (1) | AU2019375193A1 (https=) |
| BR (1) | BR112021008781A2 (https=) |
| CA (1) | CA3118843A1 (https=) |
| EA (1) | EA202190776A1 (https=) |
| IL (1) | IL282972B2 (https=) |
| MX (2) | MX2021005240A (https=) |
| PH (1) | PH12021550832A1 (https=) |
| SG (1) | SG11202104192TA (https=) |
| WO (1) | WO2020095256A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3737401A4 (en) * | 2018-01-12 | 2021-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH |
| EP4291238A4 (en) * | 2021-02-10 | 2024-10-09 | Great Novel Therapeutics Biotech & Medicals Corporation | PHARMACEUTICAL COMBINATION AND METHOD FOR OVERCOMING IMMUNE SUPPRESSION OR STIMULATING AN IMMUNE RESPONSE AGAINST CANCER |
| CN113018415B (zh) * | 2021-03-17 | 2022-07-01 | 遵义医科大学 | 一种药物组合及其应用 |
| CN113750215B (zh) * | 2021-09-24 | 2023-06-23 | 暨南大学 | 用于治疗肿瘤的联合药物 |
| WO2025083628A1 (en) | 2023-10-19 | 2025-04-24 | Aurigene Oncology Limited | Pharmaceutically acceptable salt of a cd47-sirp alpha pathway inhibitor |
| WO2025229631A2 (en) * | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER |
| US20250339404A1 (en) | 2024-05-03 | 2025-11-06 | Aurigene Oncology Limited | COMBINATION THERAPY USING A CD47-SIRP alpha BLOCKING AGENT AND AZACITIDINE |
| CN118453879B (zh) * | 2024-05-23 | 2025-10-03 | 大连医科大学附属第二医院 | 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2672828A1 (en) * | 2006-12-13 | 2008-06-26 | Schering Corporation | Methods of treatment |
| HRP20221260T1 (hr) | 2010-05-14 | 2023-03-03 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizirana i kimerna monoklonska protutijela za cd47 |
| HRP20181052T1 (hr) | 2013-09-06 | 2018-09-07 | Aurigene Discovery Technologies Limited | Derivati 1,2,4-oksadiazola kao imunomodulatori |
| EP3267985A4 (en) | 2015-03-10 | 2018-07-25 | Aurigene Discovery Technologies Limited | 3-substituted-1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| NZ734650A (en) * | 2015-03-10 | 2023-07-28 | Aurigene Oncology Ltd | 1,2,4-oxadiazole and thiadiazole compounds as immunomodulators |
| WO2016168246A1 (en) | 2015-04-14 | 2016-10-20 | The Procter & Gamble Company | Solid conditioning composition |
| CN104804093A (zh) | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | 一种针对cd47的单域抗体 |
| NZ741324A (en) | 2015-09-21 | 2021-09-24 | Erasmus Univ Medical Center | Anti-cd47 antibodies and methods of use |
| EP3243522A1 (en) | 2016-05-10 | 2017-11-15 | Université Pierre et Marie Curie (Paris 6) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death |
| DK3454879T3 (da) | 2016-05-10 | 2022-03-14 | Inst Nat Sante Rech Med | Hidtil ukendte forbindelser og farmaceutisk anvendelse deraf i behandlingen af kræft |
| WO2018047139A1 (en) | 2016-09-12 | 2018-03-15 | Aurigene Discovery Technologies Limited | Compounds as modulators of tigit signalling pathway |
| MY205585A (en) * | 2016-10-20 | 2024-10-28 | Aurigene Oncology Ltd | Dual inhibitors of vista and pd-1 pathways |
| EP3737401A4 (en) * | 2018-01-12 | 2021-09-15 | Aurigene Discovery Technologies Limited | 1,2,4-OXADIAZOLE COMPOUNDS AS INHIBITORS OF THE CD47 SIGNAL PATH |
| WO2019175799A2 (en) * | 2018-03-14 | 2019-09-19 | Aurigene Discovery Technologies Limited | Method of modulating tigit and pd-1 signalling pathways using 1,2,4-oxadiazole compounds |
-
2019
- 2019-11-08 JP JP2021524166A patent/JP7623279B2/ja active Active
- 2019-11-08 EA EA202190776A patent/EA202190776A1/ru unknown
- 2019-11-08 US US16/678,594 patent/US11311517B2/en active Active
- 2019-11-08 SG SG11202104192TA patent/SG11202104192TA/en unknown
- 2019-11-08 WO PCT/IB2019/059602 patent/WO2020095256A1/en not_active Ceased
- 2019-11-08 MX MX2021005240A patent/MX2021005240A/es unknown
- 2019-11-08 IL IL282972A patent/IL282972B2/en unknown
- 2019-11-08 BR BR112021008781-8A patent/BR112021008781A2/pt unknown
- 2019-11-08 EP EP19835717.0A patent/EP3876931A1/en not_active Withdrawn
- 2019-11-08 CA CA3118843A patent/CA3118843A1/en active Pending
- 2019-11-08 KR KR1020217014395A patent/KR20210088584A/ko not_active Ceased
- 2019-11-08 CN CN201980071532.5A patent/CN112930181B/zh active Active
- 2019-11-08 AU AU2019375193A patent/AU2019375193A1/en not_active Abandoned
- 2019-11-08 CN CN202510514794.1A patent/CN120305258A/zh active Pending
-
2021
- 2021-04-13 PH PH12021550832A patent/PH12021550832A1/en unknown
- 2021-05-04 MX MX2024006094A patent/MX2024006094A/es unknown
-
2022
- 2022-04-25 US US17/728,325 patent/US12268670B2/en active Active
-
2025
- 2025-01-16 JP JP2025006295A patent/JP2025063207A/ja active Pending
- 2025-02-04 US US19/045,376 patent/US20250177358A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7506981B2 (ja) | Ｔｌｒ７アゴニストを含む併用薬 | |
| RU2018130330A (ru) | Фармацевтические композиции и способы борьбы с кардиотоксичностью, вызванной химиотерапией | |
| JP7623279B2 (ja) | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ | |
| JP2019142911A (ja) | 薬物組み合わせ | |
| CN108712904B (zh) | 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途 | |
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| CN108430473B (zh) | 抗增殖化合物以及其药物组合物和用途 | |
| TW201740943A (zh) | Hdac抑制劑與pd-1抑制劑之組合治療 | |
| JP2016536361A (ja) | Ｃｄ３３抗体及び脱メチル剤を含む医薬配合物 | |
| CN108601777B (zh) | 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的制剂 | |
| CA3068591A1 (en) | Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide | |
| KR20200105662A (ko) | 2-(4-클로로페닐)-n-((2-(2,6-디옥소피페리딘-3-일)-1-옥소이소인돌린-5-일)메틸)-2,2-디플루오로아세트아미드의 동위 이성질체 | |
| JPWO2020095256A5 (https=) | ||
| JP2021528496A5 (https=) | ||
| CN111836621A (zh) | 使用1,2,4-噁二唑化合物调节tigit和pd-1信号传导途径的方法 | |
| JPWO2023025307A5 (https=) | ||
| EP3973964A1 (en) | Quinoline derivative used for combination treatment of small cell lung cancer | |
| CN113286614A (zh) | 用于治疗癌症的pd-1拮抗剂、atr抑制剂和铂化物质的组合 | |
| CN111973747A (zh) | 用于联合治疗卵巢癌的喹啉衍生物 | |
| CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
| RU2025105118A (ru) | Комбинированная терапия ингибиторами cdk7 с другими противораковыми агентами | |
| JPWO2022256680A5 (https=) | ||
| RU2025135585A (ru) | Кристаллическая форма ингибитора enpp1 | |
| EA045738B1 (ru) | Комбинация маломолекулярных ингибиторов cd-47 с другими противораковыми агентами | |
| HK40072142A (en) | Quinoline derivative used for combination treatment of small cell lung cancer |